94 MMWR / November 4, 2022 / Vol. 71 / No. 3
US Department of Health and Human Services/Centers for Disease Control and Prevention
151. Markman JD, Bolash RB, McAlindon TE, et al. Tanezumab for chronic
low back pain: a randomized, double-blind, placebo- and active-
controlled, phase 3 study of efficacy and safety. Pain 2020;161:2068–78.
PMID:32453139 https://doi.org/10.1097/j.pain.0000000000001928
152. Spierings ELH, Fidelholtz J, Wolfram G, Smith MD, Brown MT,
West CR. A phase III placebo- and oxycodone-controlled study of
tanezumab in adults with osteoarthritis pain of the hip or knee. Pain
2013;154:1603–12. PMID:23707270 https://doi.org/10.1016/j.
pain.2013.04.035
153. van de Donk T, van Cosburgh J, van Dasselaar T, et al. Tapentadol
treatment results in long-term pain relief in patients with chronic low
back pain and associates with reduced segmental sensitization. Pain
Rep 2020;5:e877. PMID:33364540 https://doi.org/10.1097/
PR9.0000000000000877
154. Maheu E, Soriot-Thomas S, Noel E, Ganry H, Lespessailles E, Cortet B.
Wearable transcutaneous electrical nerve stimulation (actiTENS®) is
effective and safe for the treatment of knee osteoarthritis pain: a
randomized controlled trial versus weak opioids. Ther Adv
Musculoskelet Dis 2022;14:1759720X211066233. PMID:35069809
https://doi.org/10.1177/1759720X211066233
155. Agnoli A, Xing G, Tancredi DJ, Magnan E, Jerant A, Fenton JJ.
Association of dose tapering with overdose or mental health crisis among
patients prescribed long-term opioids. JAMA 2021;326:411–9.
PMID:34342618 https://doi.org/10.1001/jama.2021.11013
156. Hallvik SE, El Ibrahimi S, Johnston K, et al. Patient outcomes after
opioid dose reduction among patients with chronic opioid therapy.
Pain 2022;163:83–90. PMID:33863865 https://doi.org/10.1097/j.
pain.0000000000002298
157. Selph S, McDonagh M, Pappas M, et al. Systematic review on
nonopioid pharmacologic treatments for chronic pain: surveillance
report 3. AHRQ publication no. 22-EHC034 Rockville, MD: Agency
for Healthcare Research and Quality; June 2022. https://
effectivehealthcare.ahrq.gov/sites/default/files/related_files/
surveillance-report-3-nonopioid-pharm-chronic-pain.pdf
158. Langford RM, Mares J, Novotna A, et al. A double-blind, randomized,
placebo-controlled, parallel-group study of THC/CBD oromucosal
spray in combination with the existing treatment regimen, in the relief
of central neuropathic pain in patients with multiple sclerosis. J Neurol
2013;260:984–97. PMID:23180178 https://doi.org/10.1007/
s00415-012-6739-4
159. Khasbage S, Shukla R, Sharma P, Singh S. A randomized control
trial of duloxetine and gabapentin in painful diabetic neuropathy.
J Diabetes 2021;13:532–41. PMID:33340245 https://doi.
org/10.1111/1753-0407.13148
160. Shahid W, Kumar R, Shaikh A, Kumar S, Jameel R, Fareed S.
Comparison of the efficacy of duloxetine and pregabalin in pain relief
associated with diabetic neuropathy. Cureus 2019;11:e5293.
PMID:31579634 https://doi.org/10.7759/cureus.5293
161. Hussain N, Said ASA, Javaid FA, et al. The efficacy and safety profile of
capsaicin 8% patch versus 5% Lidocaine patch in patients with diabetic
peripheral neuropathic pain: a randomized, placebo-controlled study of
south Asian male patients. J Diabetes Metab Disord 2021;20:271–8.
PMID:34178837 https://doi.org/10.1007/s40200-021-00741-2
162. Skelly A, Brodt E, Kantner S, Diulio-Nakamura A, Mauer K, Shetty K.
Systematic review on noninvasive nonpharmacological treatment for
chronic pain: surveillance report 3. AHRQ publication no. 22-EHC035.
Rockville, MD: Agency for Healthcare Research and Quality; June
2022. https://effectivehealthcare.ahrq.gov/sites/default/files/related_
files/surveillance-report-3-noninvasive-nonpharma.pdf
163. Xiao Z, Li G. The effect of Wuqinxi exercises on the balance function
and subjective quality of life in elderly, female knee osteoarthritis
patients. Am J Transl Res 2021;13:6710–6. PMID:34306416
164. Alqualo-Costa R, Rampazo ÉP, Thome GR, Perracini MR, Liebano RE.
Interferential current and photobiomodulation in knee osteoarthritis:
a randomized, placebo-controlled, double-blind clinical trial. Clin
Rehabil 2021;35:1413–27. PMID:33896234 https://doi.
org/10.1177/02692155211012004
165. Chou R, Griffin J, Blazina I, Schwarz E, Atchison C, Mauer K.
Systematic review on treatments for acute pain: surveillance report 3.
AHRQ publication no. 22-EHC022. Rockville, MD: Agency for
Healthcare Research and Quality; June 2022. https://effectivehealthcare.
ahrq.gov/sites/default/files/product/pdf/main-apps-surv-report-3-
acute-pain.pdf
166. Ilyas AM, Chapman T, Zmistowski B, Sandrowski K, Graham J,
Hammoud S. The effect of preoperative opioid education on opioid
consumption after outpatient orthopedic surgery: a prospective
randomized trial. Orthopedics 2021;44:123–7. PMID:33561870
https://doi.org/10.3928/01477447-20210201-07
167. Paskey T, Vincent S, Critchlow E, et al. Prospective randomized study
evaluating the effects of preoperative opioid counseling on postoperative
opioid use after outpatient lower extremity orthopaedic surgery. J Surg
Orthop Adv 2021;30:2–6. PMID:33851905
168. Zhu CY, Schumm MA, Hu TX, et al. Patient-centered decision-making
for postoperative narcotic-free endocrine surgery: a randomized clinical
trial. JAMA Surg 2021;156:e214287. PMID:34495283 https://doi.
org/10.1001/jamasurg.2021.4287
169. VanderPluym JH, Halker Singh RB, Farah MH, et al. Acute treatments
for episodic migraine: surveillance report 3. AHRQ publication
no. 22-EHC041. Rockville, MD: Agency for Healthcare Research and
Quality; August 2022. https://effectivehealthcare.ahrq.gov/sites/
default/files/product/pdf/episodic-migraine-surveillance-report-3.pdf
170. Winner PK, McAllister P, Chakhava G, et al. Effects of intravenous
eptinezumab vs placebo on headache pain and most bothersome
symptom when initiated during a migraine attack: a randomized clinical
trial. JAMA 2021;325:2348–56. PMID:34128999 https://doi.
org/10.1001/jama.2021.7665
171. Meek R, Graudins A, McDonald M, McGannon D, Limm E.
Comparing propofol with placebo for early resolution of acute migraine
in adult emergency department patients: a double-blind randomized
controlled trial. Emerg Med Australas 2021;33:465–72. https://doi.
org/10.1111/1742-6723.13659
172. Friedman BW, Irizarry E, Williams A, et al. A randomized, double-
dummy, emergency department-based study of greater occipital nerve
block with bupivacaine vs intravenous metoclopramide for treatment
of migraine. Headache 2020;60:2380–8. PMID:32981043 https://
doi.org/10.1111/head.13961
173. Hokenek NM, Ozer D, Yılmaz E, et al. Comparison of greater occipital
nerve and supra orbital nerve blocks methods in the treatment of acute
migraine attack: a randomized double-blind controlled trial. Clin
Neurol Neurosurg 2021;207:106821. PMID:34304069 https://doi.
org/10.1016/j.clineuro.2021.106821
174. Antal A, Bischoff R, Stephani C, et al. Low intensity, transcranial,
alternating current stimulation reduces migraine attack burden in a
home application set-up: a double-blinded, randomized feasibility
study. Brain Sci 2020;10:888. PMID:33233400 https://doi.
org/10.3390/brainsci10110888